These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9327523)

  • 1. IL-12 as an adjuvant for cell-mediated immunity.
    Scott P; Trinchieri G
    Semin Immunol; 1997 Oct; 9(5):285-91. PubMed ID: 9327523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S; Prussin C; Sacks DL; Seder RA
    Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis.
    Michel MY; Fathy FM; Hegazy EH; Hussein ED; Eissa MM; Said DE
    J Egypt Soc Parasitol; 2006 Apr; 36(1):159-76, following 76. PubMed ID: 16605109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
    Stobie L; Gurunathan S; Prussin C; Sacks DL; Glaichenhaus N; Wu CY; Seder RA
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8427-32. PubMed ID: 10890924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology of canine leishmaniasis.
    Barbiéri CL
    Parasite Immunol; 2006 Jul; 28(7):329-37. PubMed ID: 16842269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling of a Leishmania antigen eIF-4A: identification of a potential epitope implicated in the adjuvant effect.
    Hamza A; Kébaïer K; Vasilescu D; Sarma MH; Sarma RH
    J Biomol Struct Dyn; 2003 Aug; 21(1):43-53. PubMed ID: 12854958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
    Kuriyama H; Watanabe S; Kjaergaard J; Tamai H; Zheng R; Weinberg AD; Hu HM; Cohen PA; Plautz GE; Shu S
    Cell Immunol; 2006 Sep; 243(1):30-40. PubMed ID: 17207783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
    Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
    Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12: biological properties and clinical application.
    Del Vecchio M; Bajetta E; Canova S; Lotze MT; Wesa A; Parmiani G; Anichini A
    Clin Cancer Res; 2007 Aug; 13(16):4677-85. PubMed ID: 17699845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG; Coler RN; Campos-Neto A
    Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.
    Halliday A; Turner JD; Guimarães A; Bates PA; Taylor MJ
    Parasit Vectors; 2016 Feb; 9():96. PubMed ID: 26897363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm.
    Alexander J; Bryson K
    Immunol Lett; 2005 Jun; 99(1):17-23. PubMed ID: 15894106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cellular immunity induced by H.pylori vaccine with chitosan as adjuvant].
    Gong YF; Xie Y; Zhou NJ; Chen J; Zhou XJ; Lu NH; Wang CW
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul; 23(7):595-9. PubMed ID: 17618575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.